Drug Eluting Balloons Catheters Market Research Reveals Path To $2.91 Billion By 2030

The market for drug eluting balloon catheters is set for significant expansion over the coming years, driven by advancements in medical technology and growing demand for less invasive treatment options. This sector continues to attract attention due to its potential to improve patient outcomes in vascular therapies. Below is an in-depth look at the market's size, key players, prevailing trends, and segment dynamics shaping its future.

Steady Market Growth Expected in the Drug Eluting Balloons Catheters Market
The drug eluting balloons catheters market is projected to grow rapidly, reaching a valuation of $2.92 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 11.9%. Factors fueling this expansion include the rising demand for minimally invasive vascular treatments, increased adoption of sirolimus-based balloons, and the widening scope of peripheral vascular disease therapies. In addition, growing investments in cutting-edge catheter technologies and a stronger focus on long-term patient benefits are playing a crucial role. Key trends influencing the market include a surge in the use of drug-coated balloon technologies, expanded applications in both coronary and peripheral interventions, a shift towards stent-free treatment methods, advancements in drug coating methods, and heightened attention to preventing restenosis.

Download a free sample of the drug eluting balloons catheters market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Players Driving Innovation in the Drug Eluting Balloons Catheters Market
Several prominent companies dominate the drug eluting balloons catheters market, including Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, and Cook Medical LLC. Other notable players include Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Concept Medical Inc., Aachen Resonance GmbH, and AR Baltic Medical UAB.

Strategic Expansion Moves in the Market
In June 2023, Germany-based Translumina Therapeutics Company expanded its portfolio by acquiring Blue Medical Devices BV, a Netherlands-based firm specializing in drug-eluting balloon catheters. This acquisition aims to integrate Blue Medical's proprietary drug application technology with Translumina's existing products, enhancing their offerings in neurovascular and peripheral interventions while improving drug coating capabilities.

View the full drug eluting balloons catheters market report:
https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Cutting-Edge Developments Shaping Market Trends
Innovation continues to be a primary focus within the drug eluting balloons catheters market. Companies are investing heavily in developing next-generation products equipped with advanced features to strengthen their competitive position. For example, in March 2024, Boston Scientific Corporation announced its receipt of FDA approval for the AGENT Drug-Coated Balloon (DCB), marking the first drug-coated coronary balloon authorized in the US specifically to treat in-stent restenosis (ISR). This device incorporates a paclitaxel coating designed to deliver therapeutic doses directly to the vessel wall, effectively lowering ISR recurrence without requiring additional stents or radiation therapy. Clinical trials demonstrated a 49% reduction in heart attack risk at the treatment site alongside a low incidence of adverse effects.

Breakdown of Market Segments in the Drug Eluting Balloons Catheters Industry
This market is segmented based on product types, drugs, raw materials, and end-users. The product categories include coronary artery disease treatments, peripheral vascular disease therapies, and drug-eluting balloon catheters. Drug-wise segmentation covers paclitaxel, sirolimus, and other medications. Raw materials are categorized into nylon, polyurethane, and others. End-users encompass hospitals and clinics, ambulatory surgical centers, and catheterization laboratories. Further subsegments within coronary artery disease focus on coronary drug-eluting balloon catheters, coronary in-stent restenosis drug-eluting balloon catheters, and coronary small-vessel drug-eluting balloon catheters. Peripheral vascular disease applications include drug-eluting balloon catheters for femoro-popliteal arteries and below-the-knee (BTK) treatments. The drug-eluting balloon catheters category also highlights drug-eluting angioplasty balloon catheters.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.